Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma

Sarah A. Holstein(University of Nebraska Medical Center), Philip L. McCarthy(Roswell Park Comprehensive Cancer Center), Kouros Owzar(Duke University), Luis Isola(Mount Sinai Medical Center), Kenneth C. Anderson(Dana-Farber Cancer Institute), Paul G. Richardson(Harvard University), Thomas Martin(University of California, San Francisco), Bruce D. Cheson(Center for Cancer and Blood Disorders), Vera J. Suman(Mayo Clinic in Arizona), Thomas C. Shea(University of North Carolina at Chapel Hill), Charles Linker(University of California, San Francisco), Margarida Silverman(University of Iowa Hospitals and Clinics), Katelyn Santo(Mayo Clinic), Don M. Benson(The Ohio State University), Ravi Vij(Washington University in St. Louis)
Transplantation and Cellular Therapy
April 20, 2020
10.1016/j.bbmt.2020.03.028
Cited by 6

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k